Advances in artificial intelligence (AI) have the potential to revolutionize biopharmaceutical research and development. They also pose a host of challenges to intellectual property systems that have traditionally relied on human-centric concepts. Perhaps most importantly, the United States Federal Circuit and the United Kingdom Supreme Court have very recently held that AI-generated inventions, namely those created by generative AI systems in the absence of an identifiable, traditional human inventor, are inherently unpatentable. This panel will explore the state-of-the-law and policy on AI-generated inventions globally, the implications of recent court decisions, and what biopharma companies can do to protect themselves and the future of innovation.